Racial comparisons in treatment of rectal adenocarcinoma and survival in the military health system
JNCI Cancer Spectrum · 2024
DOI: 10.1093/jncics/pkae074 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Yvonne L Eaglehouse und 4 weiteren Autor:innen. Beteiligte Einrichtung: Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Black or African American, Healthcare Disparities, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Surgery, Uniformed Services University of the Health Sciences.
Abstract (Originalsprache)
Background
Racial disparities in treatment and outcomes of rectal cancer have been attributed to patients’ differential access to care. We aimed to study treatment and outcomes of rectal cancer in the equal access Military Health System (MHS) to better understand potential racial disparities.
Methods
We accessed the MilCanEpi database to study a cohort of patients aged 18 and older who were diagnosed with rectal adenocarcinoma between 1998 and 2014. Receipt of guideline recommended treatment per tumor stage, cancer recurrence, and all-cause death were compared between non-Hispanic White and Black patients using multivariable regression models with associations expressed as odds (AORs) or hazard ratios (AHRs) and their 95% confidence intervals (CIs).
Results
The study included 171 Black and 845 White patients with rectal adenocarcinoma. Overall, there were no differences in receipt of guideline concordant treatment (AOR = 0.76, 95% CI = 0.45 to 1.29), recurrence (AHR = 1.34, 95% CI = 0.85 to 2.12), or survival (AHR = 1.08, 95% CI = 0.77 to 1.54) for Black patients compared with White patients. However, Black patients younger than 50 years of age at diagnosis (AOR = 0.34, 95% CI = 0.13 to 0.90) or with stage III or IV tumors (AOR = 0.28, 95% CI = 0.12 to 0.64) were less likely to receive guideline recommended treatment than White patients in stratified analysis.
Conclusions
In the equal access MHS, although there were no overall racial disparities in rectal cancer treatment or clinical outcomes between Black and White patients, disparities among those with early-onset or late-stage rectal cancers were noted. This suggests that factors other than access to care may play a role in the observed disparities and warrants further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
- Department of Surgery, Division of Surgical Oncology, Walter Reed National Military Medical Center, Bethesda, MD, USA.
- Department of Preventive Medicine & Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
ORCID-Profile: Yvonne L Eaglehouse, Craig D Shriver
Förderung
- Department of Surgery, Uniformed Services University of the Health Sciences
Zitieren
APA
Eaglehouse, Y. L., Darmon, S., Gage, M. M., Shriver, C. D., & Zhu, K. (2024). Racial comparisons in treatment of rectal adenocarcinoma and survival in the military health system. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae074
Vancouver
Eaglehouse YL, Darmon S, Gage MM, Shriver CD, Zhu K. Racial comparisons in treatment of rectal adenocarcinoma and survival in the military health system. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae074
BibTeX
@article{Eaglehouse2024,
author = {Eaglehouse, Yvonne L and Darmon, Sarah and Gage, Michele M and Shriver, Craig D and Zhu, Kangmin},
title = {Racial comparisons in treatment of rectal adenocarcinoma and survival in the military health system},
journal = {JNCI Cancer Spectrum},
year = {2024},
doi = {10.1093/jncics/pkae074}
}
EUVIMED